Overview

* Biodesix Q2 2025 revenue rises 12% to $20 mln, beating analyst expectations

* Gross profit margin improves to 80%, driven by Lung Diagnostic testing growth

* Net loss widens to $11.5 mln, despite revenue growth

Outlook

* Biodesix ( BDSX ) reaffirms FY2025 revenue guidance of $80-85 mln

* Company anticipates adjusted EBITDA positivity in Q4 2025

* Biodesix ( BDSX ) sees strong growth in services business driving future results

* Company expects increased sales rep productivity to boost Q4 results

Result Drivers

* PRIMARY CARE EXPANSION - Significant increase in lung diagnostic test orders from primary care physicians, attributed to expanded commercial focus

* DEVELOPMENT SERVICES GROWTH - Revenue from Development Services rose 53%, contributing to overall revenue growth

* SALES TEAM EXPANSION - Increase in sales and marketing expenses due to expansion of sales team to support Lung Diagnostic sales growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $20 mln $18.50

Revenue mln (6

Analysts

)

Q2 Net -$11.50

Income mln

Q2 $25.70

Adjusted mln

Operatin

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Biodesix Inc ( BDSX ) is $2.00, about 80.5% above its August 6 closing price of $0.39

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)